Kunle O. Odunsi
Expertise in
7
conditions

Dr. Kunle O. Odunsi

Obstetrics and Gynecology
5758 S. Maryland Ave., 
Chicago, IL 
Accepting New Patients
Expertise in
7
conditions
5758 S. Maryland Ave., 
Chicago, IL 

Overview

Kunle Odunsi is an Obstetrics and Gynecologist practicing medicine in Chicago, Illinois.

Dr. Odunsi is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, and Testicular Yolk Sac Tumor.

Dr. Odunsi is board certified in Gynecologic Oncology. He is actively involved in clinical research, co-authoring 267 peer reviewed articles and participating in 12 clinical trials. Dr. Odunsi is currently accepting new patients.

Specialties

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in NY

Board Certifications

Gynecologic Oncology

Fellowships

Roswell Park Comprehensive Cancer Center

Hospital Affiliations

UChicago Medicine Faculty Physicians

Languages Spoken

English
Spanish
Yoruba

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO

Locations

UChicago Medicine Duchossois Center for Advanced Medicine - Hyde Park
5758 S. Maryland Ave., Chicago, IL 60637

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies
A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2026
Intervention Type: Drug, Biological, Other, Procedure
Study Drugs: Cyclophosphamide, Decitabine, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Study Phase: Phase 1/Phase 2
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2026
Intervention Type: Genetic, Radiation
Study Drug: Autologous Genetically Modified MAGE-A4c1032 T-Cells
Study Phase: Phase 1
A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian Cancer
A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Aldesleukin, Cyclophosphamide, Decitabine, NY-ESO-1-Specific T Lymphocytes
Study Phase: Phase 1
A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 13, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine, Poly ICLC
Study Phase: Phase 1/Phase 2
A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation
A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Drug, Biological, Other
Study Drugs: Durvalumab, Olaparib, Tremelimumab
Study Phase: Phase 2
A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: Aldesleukin, Melphalan, Autologous NY-ESO-1-Specific CD8-Positive T Lymphocytes
Study Phase: Phase 1
A Phase I/IIa Safety and Immunologic Efficacy Trial of Intraperitoneal Induction of CTLs Combined With Alpha-Dendritic Cell Vaccine for Primary Ovarian Cancer
A Phase I/IIa Safety and Immunologic Efficacy Trial of Intraperitoneal Induction of CTLs Combined With Alpha-Dendritic Cell Vaccine for Primary Ovarian Cancer
Enrollment Status: Withdrawn
Publish Date: November 22, 2023
Intervention Type: Biological
Study Drugs: Alpha-type-1 Polarized Dendritic Cells, Autologous Natural Killer Cell-like CTLs
Study Phase: Phase 1/Phase 2
A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Other, Drug, Biological
Study Phase: Phase 1/Phase 2
A Pilot Study of Feasibility of Performing Intravital Microscopy in Patients With Ovarian, Primary Peritoneal or Fallopian Tube Cancer
A Pilot Study of Feasibility of Performing Intravital Microscopy in Patients With Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug, Other, Procedure
Study Drug: Fluorescein Sodium
Study Phase: Early Phase 1
A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)
A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)
Enrollment Status: Unknown
Publish Date: September 19, 2019
Intervention Type: Biological
Study Drug: NKR-2 Cells
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

266 Total Publications

Correction: Oturkar et al. Estrogen Receptor-Beta2 (ERβ2)-Mutant p53-FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC). Cancers 2022, 14, 1120.
Correction: Oturkar et al. Estrogen Receptor-Beta2 (ERβ2)-Mutant p53-FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC). Cancers 2022, 14, 1120.
Journal: Cancers
Published: June 09, 2026
Similar Doctors
Expertise in
16
conditions
Dr. Sudarshan K. Sharma
Obstetrics and Gynecology
Expertise in
16
conditions
Dr. Sudarshan K. Sharma
Obstetrics and Gynecology
Referral may be required

UChicago Medicine Duchossois Center For Advanced Medicine - Hyde Park

5758 S. Maryland Ave., 
Chicago, IL 
 (0.1 miles away)
888-824-0200
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Sudarshan Sharma is an Obstetrics and Gynecologist practicing medicine in Chicago, Illinois. Dr. Sharma is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Sertoli-Leydig Cell Tumor, Oophorectomy, and Lymphadenectomy. Dr. Sharma is currently accepting new patients.

Expertise in
12
conditions
Dr. John W. Moroney
Obstetrics and Gynecology
Expertise in
12
conditions
Dr. John W. Moroney
Obstetrics and Gynecology
Referral may be required
Before you request

UChicago Medicine Orland Park

14290 S. La Grange Rd., 
Orland Park, IL 
 (16.9 miles away)
888-824-0200
Languages Spoken:
English, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

John Moroney is an Obstetrics and Gynecologist practicing medicine in Orland Park, Illinois. Dr. Moroney is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Sertoli-Leydig Cell Tumor, Gastrostomy, and Bladder Reconstruction. Dr. Moroney is board certified in Gynecologic Oncology, American Board Of Obstetrics Gynecology, and Practicing Since2002. Dr. Moroney is currently accepting new patients.

Expertise in
15
conditions
Dr. Nita K. Lee
Obstetrics and Gynecology
Expertise in
15
conditions
Dr. Nita K. Lee
Obstetrics and Gynecology
Referral may be required
Before you request

UChicago Medicine Duchossois Center For Advanced Medicine - Hyde Park

5758 S. Maryland Ave., 
Chicago, IL 
 (0.1 miles away)
888-824-0200
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Nita Lee is an Obstetrics and Gynecologist practicing medicine in Chicago, Illinois. Dr. Lee is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Hernia Surgery, and Bladder Reconstruction. Dr. Lee is board certified in Practicing Since2004 and Gynecologic Oncology. Dr. Lee is currently accepting new patients.

Frequently Asked Questions about Dr. Kunle O. Odunsi

How do I make an appointment with Dr. Kunle O. Odunsi?

You can book an appointment with Dr. Kunle O. Odunsi by calling their office at 888-824-0200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kunle O. Odunsi a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kunle O. Odunsi is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kunle O. Odunsi specialize in?

While Dr. Kunle O. Odunsi is a Obstetrics and Gynecology, they have specific expertise in Ovarian Cancer, Virilizing Ovarian Tumor, and Ovarian Carcinosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Obstetrics and Gynecology.

Does Dr. Kunle O. Odunsi participate in research or clinical trials?

Yes. Dr. Kunle O. Odunsi has published 266 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Kunle O. Odunsi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kunle O. Odunsi accept my insurance?

Dr. Kunle O. Odunsi accepts most major insurance plans, including Aetna and Humana. We recommend calling the office directly at 888-824-0200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Odunsi's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile